期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗CD_(22)抗体与淋巴瘤的治疗 被引量：3

Anti CD_(22) Monoclonal Antibody and Therapy of Lymphomas
下载PDF
导出
摘要 CD22是B淋巴细胞表达的抗原,其在恶性淋巴瘤细胞上也高度表达。LL2是鼠源性抗CD22抗体,通过131I标记LL2用于复发的非霍奇金淋巴瘤的治疗,观察其疗效及毒副作用。Epratuzumab是人源化的LL2抗体,通过对套细胞淋巴瘤的Ⅰ/Ⅱ期临床试验研究,其有效率为18%,不产生人抗鼠抗体(HAMA)。Epratuzumab与Rituxan联合治疗提高疗效。临床研究表明抗CD22抗体作为新的免疫导向治疗药物具有很好的前景。 CD22 is an antigen expressed on the surface of B lymph cell,it is also have high expression on the cell of malignant lymphoma. LL2 （epratuzumab） is a routine IgO2a antibody to the CD22 antigen （transferring receptor）, We observed its efficacy and toxicity of ^131I-lahalled-LL2 in the treatment of patients with recrudescent nonHodgkin lymphoma.Epratuzumab is a humanized LL2 （hLL2） monoclonal antibody, In phase Ⅰ/Ⅱ Trial of the treatment of mantle cell lymphoma, Epratuzumab didn＇t develope HAMA with the effective power of 18%, Using Epratuzumab and Rituxan in comblnation can promote their therapeutic efficacy. This review suggests that anti-CD22 antibody will have a good perspective as a new therapeutic medicine in immunal targeted therapy.
作者 刘黎 李少林
机构地区 重庆医科大学基础学院核医学教研室
出处 《医学综述》 2006年第6期339-341,共3页 Medical Recapitulate
关键词 淋巴瘤 免疫治疗 CD22 抗原 Lymphomas Immunotherapy CD22 Antigen
分类号 R730.51 [医药卫生—肿瘤]
  • 相关文献

参考文献16

  • 1Blasioli J, Paust S,Thomas ML, Definition of the sites of interaction between the protein tyrosine phosphatase SHP-1 and CD22 [J]. J Biol Chem, 1999,274(4) : 23003-23007.
  • 2Vittetta ES,Stone M,Amlot P, et al. Phase I immunotoxin trial in patients with B-cell lyraphoma [J]. Cancer Res, 1991,51 ( 15 ): 4052-4058.
  • 3Sato S, Tuscano JM, Inaoki M, et al. CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor[J]. Semin Immunol, 1998,10(4) :287-297.
  • 4Otipohy KL, Andersson KB, Draves KE, et al. CD22 regulates thymusindependent responses and the lifespan of B cells [ J ]. Nature, 1996,384(6610) :634-637.
  • 5Sato S, Miller AS, Inaoki M, et al. CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: Altered signaling in CD22-deficient mice[J] .Immunity, 1996,5(6) :551-562.
  • 6Shih LB, Lu HHZ, Xuan H, et al. Internalization and intracellular proccssing of an anti-B-cell lymphoma monoclonal antibody, LL-2[J]. Int J Cancer, 1994,56 ( 4 ) : 538-545.
  • 7Stein R, Belisle E, Hansen H J, et al. Epitope specificity of the anti- ( B cell lymphoma) monoclonal antibody, LL-2 [ J]. Cancer Immunol Iramun, 1993,37(5) :293-298.
  • 8Miriam H, Newton DL, Hans HJ, et al. Specifically targeting the CD22 Receptor of human B-cell lymphomaswith RNA damaging agent: a new generation of therapeutics[ J ]. Leukemia Lymphoma, 2002,43 (5) : 953-959.
  • 9Julie M, David C, Lisa G, et al. Phase trial of multiple dose 131 Iodine-MAB LL2( CD22 ) in patients with recurrent non-Hodgkin's lymphoma[J]. Leukemia Lymphoma,2000,38(1-2) :91-101.
  • 10Linden O, Tennvall J, Hindorf C, et al. ^131 I-labelled anti-CD22 MAB(LL2) in patients with B-cell lymphomas failing chemotherapy[ J]. Acta Oncol, 2002,41 ( 3 ) : 297-303.

同被引文献65

  • 1陈立慧,宋海峰,刘秀文.治疗性人源化单克隆抗体研究进展[J].中国新药杂志,2004,13(7):590-594. 被引量：10
  • 2姜文奇.恶性淋巴瘤的生物治疗进展[J].癌症,2005,24(8):1027-1032. 被引量：5
  • 3路萍萍,孟志云,周明霞,王敏伟,窦桂芳.抗CD22抗体治疗非霍奇金淋巴瘤的研究进展[J].中国实验血液学杂志,2006,14(6):1258-1261. 被引量：2
  • 4马勤芬,周惠芬,朱明清,刘丹丹,陈子兴,薛永权.51例慢性淋巴细胞白血病的免疫表型及细胞遗传学特征研究[J].中国实验血液学杂志,2007,15(4):696-699. 被引量：7
  • 5Coiffier B.Rituximab therapy in malignant lymphoma[J],2007(25).
  • 6Starlets D;Gore Y;Binsky I.Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival[J],2006(12).
  • 7Bae J;Martinson JA;Klingemann HG.Identification of CDl9 and CD20 peptides for induction of antigenspecific CTLs against B-cell malignancies[J],2005(04).
  • 8Dijoseph JF;Dougher MM;ArrneHino DC.Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin(CMC-544)for the treatment of acute lymphoblastic leukemia,2007(11).
  • 9Tsimberidou AM;Giles FJ;Estey E.The role of gemtuzumab ozogamicin in acute leukaemia therapy[J],2006(04).
  • 10Hernández-Caselles T;Martínez-Esparza M;Pérez-Oliva AB.A study of CD33(SIGLEC-3)antigen expression and function on activated human T and NK cells:two isoforms of CD33 are generated by alternative splicing[J],2006(01).

引证文献3

二级引证文献4

医学综述
2006年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部